{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T15:25:30Z","timestamp":1793805930096,"version":"4.6.1"},"reference-count":254,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001411","name":"Indian Council of Medical Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001411","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.urolonc.2026.04.294","type":"journal-article","created":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T20:22:32Z","timestamp":1779481352000},"page":"317-342","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Epigenetic signatures and risk determinants in bladder cancer: Implications for diagnostic and therapeutic interventions"],"prefix":"10.1016","volume":"44","author":[{"given":"Bhagyashree","family":"Pradhan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prahallad","family":"Mishra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pujarini","family":"Dash","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Niharika","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tirthankar","family":"Baral","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jagdish","family":"Mishra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Subhajit","family":"Chakraborty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piyasa","family":"Nandi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5641-1835","authenticated-orcid":false,"given":"Samir Kumar","family":"Patra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.urolonc.2026.04.294_bib0001","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA: Cancer J Clin"},{"issue":"1","key":"10.1016\/j.urolonc.2026.04.294_bib0002","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1038\/s41572-023-00468-9","article-title":"Bladder cancer","volume":"9","author":"Dyrskj\u00f8t","year":"2023","journal-title":"Nat Rev Dis Primers"},{"issue":"3","key":"10.1016\/j.urolonc.2026.04.294_bib0003","first-page":"209","article-title":"Global Cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA: Cancer J Clin"},{"issue":"7","key":"10.1016\/j.urolonc.2026.04.294_bib0004","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1001\/jama.2011.1142","article-title":"Association between smoking and risk of bladder cancer among men and women","volume":"306","author":"Freedman","year":"2011","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.urolonc.2026.04.294_bib0005","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/s13148-021-01029-1","article-title":"Clinical evaluation of Bladder CARE, a new epigenetic test for bladder cancer detection in urine samples","volume":"13","author":"Piatti","year":"2021","journal-title":"Clin Epigenetics"},{"issue":"6","key":"10.1016\/j.urolonc.2026.04.294_bib0006","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/j.eururo.2020.09.006","article-title":"Global trends of bladder cancer incidence and mortality, and their associations with tobacco use and gross domestic product per capita","volume":"78","author":"Teoh","year":"2020","journal-title":"Eur Urol"},{"issue":"2","key":"10.1016\/j.urolonc.2026.04.294_bib0007","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1038\/s41568-020-00313-1","article-title":"Advances in bladder cancer biology and therapy","volume":"21","author":"Tran","year":"2021","journal-title":"Nat Rev Cancer"},{"issue":"Suppl 2","key":"10.1016\/j.urolonc.2026.04.294_bib0008","doi-asserted-by":"crossref","first-page":"S84","DOI":"10.5213\/inj.1632752.376","article-title":"Genetic and epigenetic alterations in bladder cancer","volume":"20","author":"Li","year":"2016","journal-title":"Int Neurourol J"},{"key":"10.1016\/j.urolonc.2026.04.294_bib0009","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.ctrv.2017.10.004","article-title":"The prognostic role of epigenetic dysregulation in bladder cancer: a systematic review","volume":"61","author":"Casadevall","year":"2017","journal-title":"Cancer Treat Rev"},{"issue":"5","key":"10.1016\/j.urolonc.2026.04.294_bib0010","first-page":"404","article-title":"Treatment of muscle-invasive and advanced bladder cancer in 2020","volume":"70","author":"Patel","year":"2020","journal-title":"CA: Cancer J Clin"},{"issue":"1","key":"10.1016\/j.urolonc.2026.04.294_bib0011","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1111\/his.13734","article-title":"Staging of bladder cancer","volume":"74","author":"Magers","year":"2019","journal-title":"Histopathology"},{"issue":"2","key":"10.1016\/j.urolonc.2026.04.294_bib0012","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.eururo.2012.07.033","article-title":"Epidemiology and risk factors of urothelial bladder cancer","volume":"63","author":"Burger","year":"2013","journal-title":"Eur Urol"},{"issue":"6","key":"10.1016\/j.urolonc.2026.04.294_bib0013","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/S0302-2838(03)00416-0","article-title":"Malignant non-urothelial neoplasms of the urinary bladder: a review","volume":"44","author":"Dahm","year":"2003","journal-title":"Eur Urol"},{"issue":"9685","key":"10.1016\/j.urolonc.2026.04.294_bib0014","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S0140-6736(09)60491-8","article-title":"Bladder cancer","volume":"374","author":"Kaufman","year":"2009","journal-title":"Lancet (Lond Engl)"},{"issue":"4","key":"10.1016\/j.urolonc.2026.04.294_bib0015","first-page":"287","article-title":"The new (Version 9) American Joint Committee on Cancer tumor, node, metastasis staging for cervical cancer","volume":"71","author":"Olawaiye","year":"2021","journal-title":"CA: Cancer J Clin"},{"issue":"2","key":"10.1016\/j.urolonc.2026.04.294_bib0016","first-page":"93","article-title":"The Eighth edition AJCC Cancer Staging Manual: continuing to build a bridge from a population-based to a more \"personalized\" approach to cancer staging","volume":"67","author":"Amin","year":"2017","journal-title":"CA: Cancer J Clin"},{"key":"10.1016\/j.urolonc.2026.04.294_bib0017","series-title":"TNM classification of malignant tumours","first-page":"43","author":"Sobin","year":"1997"},{"issue":"5","key":"10.1016\/j.urolonc.2026.04.294_bib0018","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1080\/14737140.2017.1313119","article-title":"Tackling non-muscle invasive bladder cancer in the clinic","volume":"17","author":"Woldu","year":"2017","journal-title":"Expert Rev Anticancer Ther"},{"issue":"Suppl 2","key":"10.1016\/j.urolonc.2026.04.294_bib0019","doi-asserted-by":"crossref","first-page":"S70","DOI":"10.1038\/modpathol.2009.1","article-title":"Staging and reporting of urothelial carcinoma of the urinary bladder","volume":"22","author":"Cheng","year":"2009","journal-title":"Mod Pathol : Off J U S Can Acad Pathol Inc"},{"key":"10.1016\/j.urolonc.2026.04.294_bib0020","series-title":"AJCC Cancer Staging Manual","first-page":"747","author":"Edition","year":"2017"},{"issue":"9685","key":"10.1016\/j.urolonc.2026.04.294_bib0021","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S0140-6736(09)60491-8","article-title":"Bladder cancer","volume":"374","author":"Kaufman","year":"2009","journal-title":"Lancet (Lond Engl)"},{"issue":"8","key":"10.1016\/j.urolonc.2026.04.294_bib0022","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/s41585-024-00857-z","article-title":"Targeting histone modifiers in bladder cancer therapy - preclinical and clinical evidence","volume":"21","author":"Zhang","year":"2024","journal-title":"Nat Rev, Urol"},{"issue":"19","key":"10.1016\/j.urolonc.2026.04.294_bib0023","doi-asserted-by":"crossref","first-page":"1980","DOI":"10.1001\/jama.2020.17598","article-title":"Bladder Cancer: a review","volume":"324","author":"Lenis","year":"2020","journal-title":"JAMA"},{"issue":"11","key":"10.1016\/j.urolonc.2026.04.294_bib0029","doi-asserted-by":"crossref","first-page":"27107","DOI":"10.3390\/ijms161126000","article-title":"EZH2 in bladder cancer, a promising therapeutic target","volume":"16","author":"Mart\u00ednez-Fern\u00e1ndez","year":"2015","journal-title":"Int J Mol Sci"},{"issue":"12","key":"10.1016\/j.urolonc.2026.04.294_bib0031","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1007\/s11934-018-0861-5","article-title":"Epigenetic alterations in bladder cancer","volume":"19","author":"Porten","year":"2018","journal-title":"Curr Urol Rep"},{"key":"10.1016\/j.urolonc.2026.04.294_bib0024","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2021.817086","article-title":"Identification of prognostic biomarkers for bladder cancer based on DNA methylation profile","volume":"9","author":"Zhang","year":"2022","journal-title":"Front Cell Dev Biol"},{"issue":"20","key":"10.1016\/j.urolonc.2026.04.294_bib0025","doi-asserted-by":"crossref","first-page":"8169","DOI":"10.1158\/0008-5472.CAN-10-1335","article-title":"Unique DNA methylation patterns distinguish noninvasive and invasive urothelial cancers and establish an epigenetic field defect in premalignant tissue","volume":"70","author":"Wolff","year":"2010","journal-title":"Cancer Res"},{"issue":"5","key":"10.1016\/j.urolonc.2026.04.294_bib0026","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/j.jmoldx.2014.04.007","article-title":"Molecular classification of non\u2013muscle-invasive bladder cancer (pTa low-grade, pT1 low-grade, and pT1 high-grade subgroups) using methylation of tumor-suppressor genes","volume":"16","author":"Sacristan","year":"2014","journal-title":"J Mol Diagn"},{"key":"10.1016\/j.urolonc.2026.04.294_bib0027","article-title":"Comparative analysis of differentially mutated genes in non-muscle and muscle-invasive bladder cancer in the Chinese population by whole exome sequencing","volume":"13","author":"Wang","year":"2022","journal-title":"Front Genet"},{"issue":"1","key":"10.1016\/j.urolonc.2026.04.294_bib0028","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0259992","article-title":"Mutually exclusive mutation profiles define functionally related genes in muscle invasive bladder cancer","volume":"17","author":"Sangster","year":"2022","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.urolonc.2026.04.294_bib0030","doi-asserted-by":"crossref","first-page":"315","DOI":"10.3892\/ol.2023.13902","article-title":"The clinicopathological and prognostic significances of EZH2 expression in urological cancers: a metaanalysis and bioinformatics analysis","volume":"26","author":"Bai","year":"2023","journal-title":"Oncol Lett"},{"issue":"14","key":"10.1016\/j.urolonc.2026.04.294_bib0032","doi-asserted-by":"crossref","first-page":"723","DOI":"10.2217\/epi-2023-0235","article-title":"Epigenetic signaling and crosstalk in regulation of gene expression and disease progression","volume":"15","author":"Manna","year":"2023","journal-title":"Epigenomics"},{"issue":"1","key":"10.1016\/j.urolonc.2026.04.294_bib0033","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/npp.2012.112","article-title":"DNA methylation and its basic function","volume":"38","author":"Moore","year":"2013","journal-title":"Neuropsychopharmacol : Off Publ Am Coll Neuropsychopharmacol"},{"issue":"2","key":"10.1016\/j.urolonc.2026.04.294_bib0034","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1002\/cbic.201000195","article-title":"Structure and function of mammalian DNA methyltransferases","volume":"12","author":"Jurkowska","year":"2011","journal-title":"Chembiochem : Eur J Chem Biol"},{"issue":"2","key":"10.1016\/j.urolonc.2026.04.294_bib0035","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.bbrc.2015.04.033","article-title":"Identification and characterization of DNAzymes targeting DNA methyltransferase I for suppressing bladder cancer proliferation","volume":"461","author":"Wang","year":"2015","journal-title":"Biochem Biophys Res Commun"},{"issue":"5","key":"10.1016\/j.urolonc.2026.04.294_bib0036","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1042\/BST20170574","article-title":"Mammalian DNA methyltransferases: new discoveries and open questions","volume":"46","author":"Gowher","year":"2018","journal-title":"Biochem Soc Trans"},{"key":"10.1016\/j.urolonc.2026.04.294_bib0037","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.canlet.2017.03.029","article-title":"Oncogenic roles of DNA hypomethylation through the activation of cancer-germline genes","volume":"396","author":"Van Tongelen","year":"2017","journal-title":"Cancer Lett"},{"key":"10.1016\/j.urolonc.2026.04.294_bib0038","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.freeradbiomed.2019.01.031","article-title":"Oxidative stress and LINE-1 reactivation in bladder cancer are epigenetically linked through active chromatin formation","volume":"134","author":"Whongsiri","year":"2019","journal-title":"Free Radic Biol Med"},{"issue":"9","key":"10.1016\/j.urolonc.2026.04.294_bib0039","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1038\/sj.bjc.6690524","article-title":"DNA methylation and expression of LINE-1 and HERV-K provirus sequences in urothelial and renal cell carcinomas","volume":"80","author":"Florl","year":"1999","journal-title":"Br j cancer"},{"issue":"4","key":"10.1016\/j.urolonc.2026.04.294_bib0040","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1000917","article-title":"Hypomethylation of a LINE-1 promoter activates an alternate transcript of the MET oncogene in bladders with cancer","volume":"6","author":"Wolff","year":"2010","journal-title":"PLoS Genet"},{"issue":"1","key":"10.1016\/j.urolonc.2026.04.294_bib0041","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/0014-5793(95)01074-O","article-title":"The expression of the imprinted H19 and IGF-2 genes in human bladder carcinoma","volume":"374","author":"Elkin","year":"1995","journal-title":"FEBS Lett"},{"issue":"23","key":"10.1016\/j.urolonc.2026.04.294_bib0042","doi-asserted-by":"crossref","first-page":"2619","DOI":"10.1093\/hmg\/10.23.2619","article-title":"Large scale mapping of methylcytosines in CTCF-binding sites in the human H19 promoter and aberrant hypomethylation in human bladder cancer","volume":"10","author":"Takai","year":"2001","journal-title":"Hum Mol Genet"},{"issue":"45","key":"10.1016\/j.urolonc.2026.04.294_bib0043","doi-asserted-by":"crossref","first-page":"6765","DOI":"10.1038\/sj.onc.1208811","article-title":"Promoter CpG hypomethylation and transcription factor EGR1 hyperactivate heparanase expression in bladder cancer","volume":"24","author":"Ogishima","year":"2005","journal-title":"Oncogene"},{"issue":"1","key":"10.1016\/j.urolonc.2026.04.294_bib0045","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.eururo.2011.04.020","article-title":"Evaluation of the methylation status of tumour suppressor genes for predicting bacillus Calmette-Gu\u00e9rin response in patients with T1G3 high-risk bladder tumours","volume":"60","author":"Agundez","year":"2011","journal-title":"Eur Urol"},{"issue":"6","key":"10.1016\/j.urolonc.2026.04.294_bib0046","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/j.eururo.2012.01.011","article-title":"Genome-wide analysis of CpG island methylation in bladder cancer identified TBX2, TBX3, GATA2, and ZIC4 as pTa-specific prognostic markers","volume":"61","author":"Kandimalla","year":"2012","journal-title":"Eur Urol"},{"issue":"17","key":"10.1016\/j.urolonc.2026.04.294_bib0048","doi-asserted-by":"crossref","first-page":"5582","DOI":"10.1158\/1078-0432.CCR-10-2659","article-title":"Comprehensive genome methylation analysis in bladder cancer: identification and validation of novel methylated genes and application of these as urinary tumor markers","volume":"17","author":"Reinert","year":"2011","journal-title":"Clin Cancer Res : Off J Am Assoc Cancer Res"},{"issue":"14","key":"10.1016\/j.urolonc.2026.04.294_bib0060","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1093\/jnci\/djj265","article-title":"Quantitation of promoter methylation of multiple genes in urine DNA and bladder cancer detection","volume":"98","author":"Hoque","year":"2006","journal-title":"J Natl Cancer Inst"},{"issue":"2","key":"10.1016\/j.urolonc.2026.04.294_bib0061","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.ajpath.2011.05.009","article-title":"KISS1 methylation and expression as tumor stratification biomarkers and clinical outcome prognosticators for bladder cancer patients","volume":"179","author":"Cebrian","year":"2011","journal-title":"Am J Pathol"},{"issue":"2","key":"10.1016\/j.urolonc.2026.04.294_bib0054","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.urolonc.2009.01.003","article-title":"Quantitative methylation analysis of BCL2, hTERT, and DAPK promoters in urine sediment for the detection of non-muscle-invasive urothelial carcinoma of the bladder: a prospective, two-center validation study","volume":"29","author":"Vinci","year":"2011","journal-title":"Urol Oncol"},{"issue":"2","key":"10.1016\/j.urolonc.2026.04.294_bib0053","first-page":"464","article-title":"Hypermethylation of multiple genes in tumor tissues and voided urine in urinary bladder cancer patients","volume":"8","author":"Chan","year":"2002","journal-title":"Clin Cancer Res : Off J Am Assoc Cancer Res"},{"issue":"7","key":"10.1016\/j.urolonc.2026.04.294_bib0055","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.1158\/1078-0432.CCR-06-2476","article-title":"Promoter hypermethylation identifies progression risk in bladder cancer","volume":"13","author":"Yates","year":"2007","journal-title":"Clin Cancer Res"},{"issue":"24","key":"10.1016\/j.urolonc.2026.04.294_bib0044","first-page":"8659","article-title":"Aberrant promoter methylation profile of bladder cancer and its relationship to clinicopathological features","volume":"61","author":"Maruyama","year":"2001","journal-title":"Cancer Res"},{"key":"10.1016\/j.urolonc.2026.04.294_bib0056","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/1755-8794-4-45","article-title":"Distinct DNA methylation epigenotypes in bladder cancer from different Chinese sub-populations and its implication in cancer detection using voided urine","volume":"4","author":"Chen","year":"2011","journal-title":"BMC Med Genom"},{"issue":"12","key":"10.1016\/j.urolonc.2026.04.294_bib0062","first-page":"4618","article-title":"MDR1 gene overexpression and altered degree of methylation at the promoter region in bladder cancer during chemotherapeutic treatment","volume":"6","author":"Tada","year":"2000","journal-title":"Clin Cancer Res : Off J Am Assoc Cancer Res"},{"issue":"8","key":"10.1016\/j.urolonc.2026.04.294_bib0063","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0012334","article-title":"Identification of methylated genes associated with aggressive bladder cancer","volume":"5","author":"Marsit","year":"2010","journal-title":"PloS One"},{"issue":"3","key":"10.1016\/j.urolonc.2026.04.294_bib0082","doi-asserted-by":"crossref","DOI":"10.15252\/embr.201846821","article-title":"The lysine-specific methyltransferase KMT2C\/MLL3 regulates DNA repair components in cancer","volume":"20","author":"Rampias","year":"2019","journal-title":"EMBO rep"},{"key":"10.1016\/j.urolonc.2026.04.294_bib0083","article-title":"KMT2D inhibits the growth and metastasis of bladder cancer cells by maintaining the tumor suppressor genes","volume":"115","author":"Sun","year":"2019","journal-title":"Biomed Pharmacother = Biomed Pharmacother"},{"issue":"3","key":"10.1016\/j.urolonc.2026.04.294_bib0084","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.eururo.2020.11.008","article-title":"Does a novel mutagenic process target KMT2D mutation in the most common first event on the path to bladder cancer?","volume":"79","author":"Baker","year":"2021","journal-title":"Eur Urol"},{"issue":"21","key":"10.1016\/j.urolonc.2026.04.294_bib0085","doi-asserted-by":"crossref","first-page":"10342","DOI":"10.18632\/oncotarget.1867","article-title":"Pharmacologic down-regulation of EZH2 suppresses bladder cancer in vitro and in vivo","volume":"5","author":"Tang","year":"2014","journal-title":"Oncotarget"},{"issue":"10","key":"10.1016\/j.urolonc.2026.04.294_bib0086","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1038\/s41418-019-0278-9","article-title":"Inhibition of EZH2 induces NK cell-mediated differentiation and death in muscle-invasive bladder cancer","volume":"26","author":"Ramakrishnan","year":"2019","journal-title":"Cell Death Differ"},{"key":"10.1016\/j.urolonc.2026.04.294_bib0089","first-page":"1157","article-title":"Protein arginine methyltransferase 5 promotes bladder cancer growth through inhibiting NF-kB dependent apoptosis","volume":"17","author":"Hu","year":"2018","journal-title":"EXCLI j"},{"issue":"9","key":"10.1016\/j.urolonc.2026.04.294_bib0088","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0138390","article-title":"G9a Inhibition induces autophagic cell death via AMPK\/mTOR pathway in bladder transitional cell carcinoma","volume":"10","author":"Li","year":"2015","journal-title":"PloS one"},{"issue":"3","key":"10.1016\/j.urolonc.2026.04.294_bib0091","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1002\/ijc.25349","article-title":"Overexpression of LSD1 contributes to human carcinogenesis through chromatin regulation in various cancers","volume":"128","author":"Hayami","year":"2011","journal-title":"Int J Cancer"},{"issue":"3","key":"10.1016\/j.urolonc.2026.04.294_bib0092","doi-asserted-by":"crossref","first-page":"E179","DOI":"10.1002\/ijc.26501","article-title":"The JmjC domain-containing histone demethylase KDM3A is a positive regulator of the G1\/S transition in cancer cells via transcriptional regulation of the HOXA1 gene","volume":"131","author":"Cho","year":"2012","journal-title":"Int J Cancer"},{"issue":"4","key":"10.1016\/j.urolonc.2026.04.294_bib0093","first-page":"1431","article-title":"Upregulation of JMJD2A promotes migration and invasion in bladder cancer through regulation of SLUG","volume":"42","author":"Wang","year":"2019","journal-title":"Oncol Rep"},{"issue":"12","key":"10.1016\/j.urolonc.2026.04.294_bib0090","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1002\/mc.20758","article-title":"Role of androgen receptor and associated lysine-demethylase coregulators, LSD1 and JMJD2A, in localized and advanced human bladder cancer","volume":"50","author":"Kauffman","year":"2011","journal-title":"Mol Carcnogenes"},{"key":"10.1016\/j.urolonc.2026.04.294_bib0094","doi-asserted-by":"crossref","DOI":"10.1158\/1078-0432.CCR-14-0330","article-title":"Concurrent alterations in TERT, KDM6A, and the BRCA pathway in bladder cancer","author":"Nickerson","year":"2014","journal-title":"Clin Cancer Res : Off J Am Assoc Cancer"},{"issue":"8","key":"10.1016\/j.urolonc.2026.04.294_bib0095","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1158\/1078-0432.CCR-19-2230","article-title":"Kdm6a Deficiency activates inflammatory pathways, promotes M2 macrophage polarization, and causes bladder cancer in cooperation with p53 dysfunction","volume":"26","author":"Kobatake","year":"2020","journal-title":"Clin Cancer Res : Off J Am Assoc Cancer Res"},{"issue":"378","key":"10.1016\/j.urolonc.2026.04.294_bib0096","doi-asserted-by":"crossref","first-page":"eaai8312","DOI":"10.1126\/scitranslmed.aai8312","article-title":"Loss of tumor suppressor KDM6A amplifies PRC2-regulated transcriptional repression in bladder cancer and can be targeted through inhibition of EZH2","volume":"9","author":"Ler","year":"2017","journal-title":"Sci Transl Med"},{"issue":"16","key":"10.1016\/j.urolonc.2026.04.294_bib0097","doi-asserted-by":"crossref","first-page":"5658","DOI":"10.3390\/ijms21165658","article-title":"Histone demethylase KDM7A regulates androgen receptor activity, and its chemical inhibitor TC-E 5002 overcomes cisplatin-resistance in bladder cancer cells","volume":"21","author":"Lee","year":"2020","journal-title":"Int J Mol Sci"},{"issue":"3","key":"10.1016\/j.urolonc.2026.04.294_bib0087","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1002\/mc.22084","article-title":"Emodin modulates epigenetic modifications and suppresses bladder carcinoma cell growth","volume":"54","author":"Cha","year":"2015","journal-title":"Mol Carcinog"},{"key":"10.1016\/j.urolonc.2026.04.294_bib0079","doi-asserted-by":"crossref","first-page":"502","DOI":"10.3389\/fonc.2018.00502","article-title":"The histone H3 lysine 4 presenter WDR5 as an oncogenic protein and novel epigenetic target in cancer","volume":"8","author":"Lu","year":"2018","journal-title":"Front Oncol"},{"issue":"8","key":"10.1016\/j.urolonc.2026.04.294_bib0074","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/s41585-024-00857-z","article-title":"Targeting histone modifiers in bladder cancer therapy - preclinical and clinical evidence","volume":"21","author":"Zhang","year":"2024","journal-title":"Nat Rev, Urol"},{"issue":"7","key":"10.1016\/j.urolonc.2026.04.294_bib0113","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.3390\/ijms18071449","article-title":"Differential effects of histone acetyltransferase GCN5 or PCAF knockdown on urothelial carcinoma cells","volume":"18","author":"Koutsogiannouli","year":"2017","journal-title":"Int J Mol Sci"},{"issue":"2","key":"10.1016\/j.urolonc.2026.04.294_bib0114","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1038\/emboj.2010.318","article-title":"Distinct roles of GCN5\/PCAF-mediated H3K9ac and CBP\/p300-mediated H3K18\/27ac in nuclear receptor transactivation","volume":"30","author":"Jin","year":"2011","journal-title":"EMBO J"},{"issue":"6","key":"10.1016\/j.urolonc.2026.04.294_bib0115","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.7150\/ijbs.32332","article-title":"A CRISPR interference of CBP and p300 selectively induced synthetic lethality in bladder cancer cells In vitro","volume":"15","author":"Li","year":"2019","journal-title":"Int J Biol Sci"},{"issue":"1","key":"10.1016\/j.urolonc.2026.04.294_bib0116","first-page":"173","article-title":"p300 mediates cellular resistance to doxorubicin in bladder cancer","volume":"5","author":"Takeuchi","year":"2012","journal-title":"Mol Med Rep"},{"issue":"2","key":"10.1016\/j.urolonc.2026.04.294_bib0117","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1158\/1535-7163.MCT-15-0618","article-title":"Inhibition of class I histone deacetylases 1 and 2 promotes urothelial carcinoma cell death by various mechanisms","volume":"15","author":"Pinkerneil","year":"2016","journal-title":"Mol Cancer Ther"},{"issue":"9","key":"10.1016\/j.urolonc.2026.04.294_bib0118","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.3390\/ijms20092135","article-title":"HDAC5 Expression in urothelial carcinoma cell lines inhibits long-term proliferation but can promote epithelial-to-mesenchymal transition","volume":"20","author":"Jaguva Vasudevan","year":"2019","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.urolonc.2026.04.294_bib0126","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/1479-5876-5-49","article-title":"The histone deacetylase inhibitor belinostat (PXD101) suppresses bladder cancer cell growth in vitro and in vivo","volume":"5","author":"Buckley","year":"2007","journal-title":"J Transl Med"},{"issue":"2","key":"10.1016\/j.urolonc.2026.04.294_bib0120","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/s13577-019-00237-5","article-title":"SIRT1 promotes GLUT1 expression and bladder cancer progression via regulation of glucose uptake","volume":"32","author":"Chen","year":"2019","journal-title":"Hum Cell"},{"issue":"5","key":"10.1016\/j.urolonc.2026.04.294_bib0119","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.3390\/cancers12051066","article-title":"Sirtuins' Deregulation in bladder cancer: SIRT7 is implicated in tumor progression through epithelial to mesenchymal transition promotion","volume":"12","author":"Monteiro-Reis","year":"2020","journal-title":"Cancers"},{"issue":"12","key":"10.1016\/j.urolonc.2026.04.294_bib0121","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1038\/s41419-024-07321-1","article-title":"Mechanistic insights into SIRT7 and EZH2 regulation of cisplatin resistance in bladder cancer cells","volume":"15","author":"Cao","year":"2024","journal-title":"Cell Death Dis"},{"issue":"5","key":"10.1016\/j.urolonc.2026.04.294_bib0110","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1158\/1535-7163.MCT-15-0750","article-title":"BRD4 Regulates EZH2 transcription through upregulation of C-MYC and represents a novel therapeutic target in bladder cancer","volume":"15","author":"Wu","year":"2016","journal-title":"Mol Cancer Ther"},{"issue":"7","key":"10.1016\/j.urolonc.2026.04.294_bib0111","first-page":"4231","article-title":"Bromodomain 4 protein is a predictor of survival for urothelial carcinoma of bladder","volume":"7","author":"Yan","year":"2014","journal-title":"Int J Clin Exp Pathol"},{"issue":"2","key":"10.1016\/j.urolonc.2026.04.294_bib0112","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1139\/bcb-2021-0552","article-title":"BRD4 promotes the migration and invasion of bladder cancer cells through the Sonic hedgehog signaling pathway and enhances cisplatin resistance","volume":"100","author":"Liu","year":"2022","journal-title":"Biochem Cell Biol = Biochim biol cell"},{"issue":"2","key":"10.1016\/j.urolonc.2026.04.294_bib0047","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/s13277-011-0310-2","article-title":"Hypermethylation in bladder cancer: biological pathways and translational applications","volume":"33","author":"S\u00e1nchez-Carbayo","year":"2012","journal-title":"Tumor Biol"},{"issue":"4","key":"10.1016\/j.urolonc.2026.04.294_bib0049","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1007\/s10147-008-0811-1","article-title":"Epigenetics in bladder cancer","volume":"13","author":"Enokida","year":"2008","journal-title":"Int J Clin Oncol"},{"issue":"6","key":"10.1016\/j.urolonc.2026.04.294_bib0050","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1002\/ijc.21971","article-title":"Regularly methylated novel pro-apoptotic genes associated with recurrence in transitional cell carcinoma of the bladder","volume":"119","author":"Christoph","year":"2006","journal-title":"Int J Cancer"},{"issue":"22","key":"10.1016\/j.urolonc.2026.04.294_bib0051","doi-asserted-by":"crossref","first-page":"7457","DOI":"10.1158\/1078-0432.CCR-04-0930","article-title":"Detection of methylated apoptosis-associated genes in urine sediments of bladder cancer patients","volume":"10","author":"Friedrich","year":"2004","journal-title":"Clin Cancer Res : Off J Am Assoc Cancer Res"},{"issue":"17","key":"10.1016\/j.urolonc.2026.04.294_bib0052","doi-asserted-by":"crossref","first-page":"2769","DOI":"10.1016\/j.ejca.2005.07.019","article-title":"Prognostic relevance of methylation markers in patients with non-muscle invasive bladder carcinoma","volume":"41","author":"Friedrich","year":"2005","journal-title":"Eur J Cancer (Oxf Engl : 1990)"},{"issue":"4","key":"10.1016\/j.urolonc.2026.04.294_bib0057","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1097\/01.ju.0000046242.55722.1c","article-title":"Hypermethylation of an E-cadherin (CDH1) promoter region in high grade transitional cell carcinoma of the bladder comprising carcinoma in situ","volume":"169","author":"Horikawa","year":"2003","journal-title":"J Urol"},{"issue":"8","key":"10.1016\/j.urolonc.2026.04.294_bib0058","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1093\/carcin\/bgm116","article-title":"Promoter hypermethylation is associated with current smoking, age, gender and survival in bladder cancer","volume":"28","author":"Marsit","year":"2007","journal-title":"Carcinogenesis"},{"issue":"3","key":"10.1016\/j.urolonc.2026.04.294_bib0059","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/j.bbrc.2005.11.072","article-title":"p16INK4a and p14ARF methylation as a potential biomarker for human bladder cancer","volume":"339","author":"Kawamoto","year":"2006","journal-title":"Biochem Biophys Res Commun"},{"issue":"4","key":"10.1016\/j.urolonc.2026.04.294_bib0064","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/S0022-2836(02)00676-9","article-title":"Zebularine: a novel DNA methylation inhibitor that forms a covalent complex with DNA methyltransferases","volume":"321","author":"Zhou","year":"2002","journal-title":"J Mol Biol"},{"issue":"5","key":"10.1016\/j.urolonc.2026.04.294_bib0065","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1093\/jnci\/95.5.399","article-title":"Inhibition of DNA methylation and reactivation of silenced genes by zebularine","volume":"95","author":"Cheng","year":"2003","journal-title":"J Natl Cancer Inst"},{"issue":"12","key":"10.1016\/j.urolonc.2026.04.294_bib0066","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1038\/sj.bjc.6603482","article-title":"Methylation of tumour suppressor genes APAF-1 and DAPK-1 and in vitro effects of demethylating agents in bladder and kidney cancer","volume":"95","author":"Christoph","year":"2006","journal-title":"Br J Cancer"},{"issue":"4","key":"10.1016\/j.urolonc.2026.04.294_bib0067","first-page":"343","article-title":"5-Aza-2\u2032-deoxycytidine enhances maspin expression and inhibits proliferation, migration, and invasion of the bladder cancer T24 cell line","volume":"28","author":"Zhang","year":"2013","journal-title":"Cancer Biother Radiopharm"},{"issue":"8","key":"10.1016\/j.urolonc.2026.04.294_bib0068","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.3390\/cells9081850","article-title":"DNA methylation as a therapeutic target for bladder cancer","volume":"9","author":"Nunes","year":"2020","journal-title":"Cells"},{"issue":"5","key":"10.1016\/j.urolonc.2026.04.294_bib0069","first-page":"5652","article-title":"Role of 5-aza-CdR in mitomycin-C chemosensitivity of T24 bladder cancer cells","volume":"14","author":"Zhang","year":"2017","journal-title":"Oncol Lett"},{"key":"10.1016\/j.urolonc.2026.04.294_bib0070","first-page":"1698","article-title":"Curcumin modulates microRNA-203-mediated regulation of the src-akt axis in bladder cancer","volume":"4","author":"Saini","year":"2011"},{"issue":"5","key":"10.1016\/j.urolonc.2026.04.294_bib0071","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1007\/s00280-020-04073-5","article-title":"Intravenous 5-fluoro-2\u2032-deoxycytidine administered with tetrahydrouridine increases the proportion of p16-expressing circulating tumor cells in patients with advanced solid tumors","volume":"85","author":"Coyne","year":"2020","journal-title":"Cancer Chemother Pharmacol"},{"issue":"7","key":"10.1016\/j.urolonc.2026.04.294_bib0072","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1158\/1078-0432.CCR-20-3946","article-title":"Phase I trial of DNA methyltransferase inhibitor guadecitabine combined with cisplatin and gemcitabine for solid malignancies including urothelial carcinoma (SPIRE)","volume":"27","author":"Crabb","year":"2021","journal-title":"Clin Cancer Res : Off J Am Assoc Cancer Res"},{"issue":"7","key":"10.1016\/j.urolonc.2026.04.294_bib0073","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1038\/s41591-019-0499-y","article-title":"Inhibition of a G9a\/DNMT network triggers immune-mediated bladder cancer regression","volume":"25","author":"Segovia","year":"2019","journal-title":"Nat Med"},{"issue":"4","key":"10.1016\/j.urolonc.2026.04.294_bib0099","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1038\/s41417-024-00725-3","article-title":"Retinoids and EZH2 inhibitors cooperate to orchestrate anti-oncogenic effects on bladder cancer cells","volume":"31","author":"Ozgun","year":"2024","journal-title":"Cancer Gene Ther"},{"issue":"1","key":"10.1016\/j.urolonc.2026.04.294_bib0100","first-page":"907","article-title":"EZH2 inhibition suppresses bladder cancer cell growth and metastasis via the JAK2\/STAT3 signaling pathway","volume":"18","author":"Chen","year":"2019","journal-title":"Oncol Lett"},{"issue":"8","key":"10.1016\/j.urolonc.2026.04.294_bib0101","doi-asserted-by":"crossref","first-page":"590","DOI":"10.2174\/0118715206259585240105051941","article-title":"An expedition on synthetic methodology of FDA-approved anticancer drugs (2018-2021)","volume":"24","author":"Vishakha","year":"2024","journal-title":"Anti-Cancer Agents Med Chem"},{"issue":"40","key":"10.1016\/j.urolonc.2026.04.294_bib0102","doi-asserted-by":"crossref","first-page":"eabo8043","DOI":"10.1126\/sciadv.abo8043","article-title":"Immune activation is essential for the antitumor activity of EZH2 inhibition in urothelial carcinoma","volume":"8","author":"Piunti","year":"2022","journal-title":"Sci Adv"},{"issue":"4","key":"10.1016\/j.urolonc.2026.04.294_bib0103","doi-asserted-by":"crossref","first-page":"2646","DOI":"10.1021\/acs.jmedchem.2c01607","article-title":"Design, synthesis, and biological evaluation of a potent dual EZH2-BRD4 inhibitor for the treatment of some solid tumors","volume":"66","author":"Huang","year":"2023","journal-title":"J Med Chem"},{"issue":"8","key":"10.1016\/j.urolonc.2026.04.294_bib0104","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1038\/s41401-018-0205-5","article-title":"Inhibition of G9a by a small molecule inhibitor, UNC0642, induces apoptosis of human bladder cancer cells","volume":"40","author":"Cao","year":"2019","journal-title":"Acta pharmacol Sin"},{"issue":"1","key":"10.1016\/j.urolonc.2026.04.294_bib0105","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1186\/s13046-022-02500-4","article-title":"Flavokawain A is a natural inhibitor of PRMT5 in bladder cancer","volume":"41","author":"Liu","year":"2022","journal-title":"J Exp Clin Cancer Res : CR"},{"key":"10.1016\/j.urolonc.2026.04.294_bib0106","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.3389\/fonc.2020.01234","article-title":"LSD1 Promotes bladder cancer progression by upregulating LEF1 and enhancing EMT","volume":"10","author":"Xie","year":"2020","journal-title":"Front Oncol"},{"issue":"1","key":"10.1016\/j.urolonc.2026.04.294_bib0107","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1186\/s13046-021-01989-5","article-title":"Targeting WD repeat domain 5 enhances chemosensitivity and inhibits proliferation and programmed death-ligand 1 expression in bladder cancer","volume":"40","author":"Zhang","year":"2021","journal-title":"J Exp Clin Cancer Res : CR"},{"issue":"5","key":"10.1016\/j.urolonc.2026.04.294_bib0122","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1002\/ijc.20634","article-title":"Histone deacetylase inhibitors upregulate plakoglobin expression in bladder carcinoma cells and display antineoplastic activity in vitro and in vivo","volume":"113","author":"Canes","year":"2005","journal-title":"Int J Cancer"},{"issue":"17","key":"10.1016\/j.urolonc.2026.04.294_bib0123","first-page":"6592","article-title":"The mechanism of the growth-inhibitory effect of coxsackie and adenovirus receptor (CAR) on human bladder cancer: a functional analysis of car protein structure","volume":"61","author":"Okegawa","year":"2001","journal-title":"Cancer Res"},{"issue":"7","key":"10.1016\/j.urolonc.2026.04.294_bib0124","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/sj.cgt.7700726","article-title":"Histone deacetylase inhibitors upregulate expression of the coxsackie adenovirus receptor (CAR) preferentially in bladder cancer cells","volume":"11","author":"Sachs","year":"2004","journal-title":"Cancer Gene Ther"},{"issue":"1","key":"10.1016\/j.urolonc.2026.04.294_bib0125","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41420-023-01786-3","article-title":"Modulation of tumor microenvironment by targeting histone acetylation in bladder cancer","volume":"10","author":"Nunes","year":"2024","journal-title":"Cell Death Discov"},{"issue":"10","key":"10.1016\/j.urolonc.2026.04.294_bib0127","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1097\/CAD.0b013e32834a2c70","article-title":"HDAC inhibition delays cell cycle progression of human bladder cancer cells in vitro","volume":"22","author":"Vallo","year":"2011","journal-title":"Anti-Cancer Drugs"},{"issue":"8","key":"10.1016\/j.urolonc.2026.04.294_bib0128","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1016\/j.urolonc.2012.06.015","article-title":"Changes in histone deacetylase (HDAC) expression patterns and activity of HDAC inhibitors in urothelial cancers","volume":"31","author":"Niegisch","year":"2013","journal-title":"Urol Oncol"},{"key":"10.1016\/j.urolonc.2026.04.294_bib0129","doi-asserted-by":"crossref","first-page":"2572","DOI":"10.1200\/JCO.2019.37.15_suppl.2572","article-title":"Immunomodulation by HDAC inhibition: results from a phase Ib study with vorinostat and pembrolizumab in metastatic urothelial, renal, and prostate carcinoma patients","volume":"37","author":"Pili","year":"2019","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.urolonc.2026.04.294_bib0130","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1016\/j.urolonc.2008.11.018","article-title":"Experimental study on inhibitory effects of histone deacetylase inhibitor MS-275 and TSA on bladder cancer cells","volume":"28","author":"Qu","year":"2010","journal-title":"Urol Oncol"},{"issue":"8","key":"10.1016\/j.urolonc.2026.04.294_bib0131","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1002\/ijc.22405","article-title":"The use of histone deacetylase inhibitor FK228 and DNA hypomethylation agent 5-azacytidine in human bladder cancer therapy","volume":"120","author":"Karam","year":"2007","journal-title":"Int J Cancer"},{"key":"10.1016\/j.urolonc.2026.04.294_bib0133","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13148-017-0434-3","article-title":"Combined inhibition of BET proteins and class I HDACs synergistically induces apoptosis in urothelial carcinoma cell lines","volume":"10","author":"H\u00f6lscher","year":"2018","journal-title":"Clin Epigenetics"},{"issue":"4","key":"10.1016\/j.urolonc.2026.04.294_bib0134","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1002\/cncr.31817","article-title":"Mocetinostat for patients with previously treated, locally advanced\/metastatic urothelial carcinoma and inactivating alterations of acetyltransferase genes","volume":"125","author":"Grivas","year":"2019","journal-title":"Cancer"},{"issue":"42","key":"10.1016\/j.urolonc.2026.04.294_bib0137","doi-asserted-by":"crossref","first-page":"6081","DOI":"10.1038\/s41388-021-01999-9","article-title":"SRT1720 inhibits the growth of bladder cancer in organoids and murine models through the SIRT1-HIF axis","volume":"40","author":"Tan","year":"2021","journal-title":"Oncogene"},{"issue":"2","key":"10.1016\/j.urolonc.2026.04.294_bib0138","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.bbrc.2018.11.120","article-title":"Identification of a novel SIRT7 inhibitor as anticancer drug candidate","volume":"508","author":"Kim","year":"2019","journal-title":"Biochem Biophys Res Commun"},{"issue":"1","key":"10.1016\/j.urolonc.2026.04.294_bib0075","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.biochi.2006.07.009","article-title":"The control of histone lysine methylation in epigenetic regulation","volume":"89","author":"V\u00f6lkel","year":"2007","journal-title":"Biochimie"},{"issue":"13","key":"10.1016\/j.urolonc.2026.04.294_bib0076","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1016\/j.febslet.2010.11.010","article-title":"Histone arginine methylation","volume":"585","author":"Di Lorenzo","year":"2011","journal-title":"FEBS Lett"},{"issue":"6","key":"10.1016\/j.urolonc.2026.04.294_bib0077","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.2217\/epi.15.39","article-title":"Methyl-CpG-binding domain proteins: readers of the epigenome","volume":"7","author":"Du","year":"2015","journal-title":"Epigenomics"},{"key":"10.1016\/j.urolonc.2026.04.294_bib0078","doi-asserted-by":"crossref","DOI":"10.1016\/j.cbpa.2023.102286","article-title":"Chemical tools targeting readers of lysine methylation","volume":"74","author":"Ortiz","year":"2023","journal-title":"Curr Opin Chem Biol"},{"issue":"9","key":"10.1016\/j.urolonc.2026.04.294_bib0080","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1002\/cncr.20199","article-title":"Methyl-CpG-binding domain 2: a protective role in bladder carcinoma","volume":"100","author":"Zhu","year":"2004","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.urolonc.2026.04.294_bib0081","first-page":"165","article-title":"The engagement of histone lysine methyltransferases with nucleosomes: structural basis, regulatory mechanisms, and therapeutic implications","volume":"14","author":"Li","year":"2023","journal-title":"Protein cell"},{"issue":"9","key":"10.1016\/j.urolonc.2026.04.294_bib0098","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1038\/s41585-023-00761-y","article-title":"The androgen receptor in bladder cancer","volume":"20","author":"Chen","year":"2023","journal-title":"Nat Rev, Urol"},{"issue":"1","key":"10.1016\/j.urolonc.2026.04.294_bib0108","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.cell.2012.02.013","article-title":"Histone recognition and large-scale structural analysis of the human bromodomain family","volume":"149","author":"Filippakopoulos","year":"2012","journal-title":"Cell"},{"issue":"19","key":"10.1016\/j.urolonc.2026.04.294_bib0109","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1038\/s41388-023-02662-1","article-title":"Epigenomic mapping identifies an enhancer repertoire that regulates cell identity in bladder cancer through distinct transcription factor networks","volume":"42","author":"Neyret-Kahn","year":"2023","journal-title":"Oncogene"},{"issue":"8","key":"10.1016\/j.urolonc.2026.04.294_bib0166","first-page":"2228","article-title":"An epidemiological evaluation of the causes of cancer of the pancreas","volume":"35","author":"Wynder","year":"1975","journal-title":"Cancer Res"},{"issue":"2","key":"10.1016\/j.urolonc.2026.04.294_bib0132","doi-asserted-by":"crossref","first-page":"337","DOI":"10.3390\/cancers12020337","article-title":"Combination of decitabine and entinostat synergistically inhibits urothelial bladder cancer cells via activation of FoxO1","volume":"12","author":"Wang","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.urolonc.2026.04.294_bib0135","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13148-017-0434-3","article-title":"Combined inhibition of BET proteins and class I HDACs synergistically induces apoptosis in urothelial carcinoma cell lines","volume":"10","author":"H\u00f6lscher","year":"2018","journal-title":"Clin Epigenetics"},{"issue":"10","key":"10.1016\/j.urolonc.2026.04.294_bib0136","doi-asserted-by":"crossref","first-page":"4792","DOI":"10.1002\/cam4.2385","article-title":"BET inhibitor JQ1 suppresses cell proliferation via inducing autophagy and activating LKB1\/AMPK in bladder cancer cells","volume":"8","author":"Li","year":"2019","journal-title":"Cancer Med"},{"issue":"1","key":"10.1016\/j.urolonc.2026.04.294_bib0139","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1038\/s41420-021-00665-z","article-title":"Biological functions and clinical significance of long noncoding RNAs in bladder cancer","volume":"7","author":"Zhang","year":"2021","journal-title":"Cell Death Discov"},{"issue":"1","key":"10.1016\/j.urolonc.2026.04.294_bib0140","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1186\/s12943-017-0714-8","article-title":"Hypoxic exosomes facilitate bladder tumor growth and development through transferring long non-coding RNA-UCA1","volume":"16","author":"Xue","year":"2017","journal-title":"Mol Cancer"},{"issue":"7","key":"10.1016\/j.urolonc.2026.04.294_bib0141","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1038\/nrurol.2013.113","article-title":"Aberrant expression of microRNAs in bladder cancer","volume":"10","author":"Yoshino","year":"2013","journal-title":"Nat Rev, Urol"},{"issue":"2","key":"10.1016\/j.urolonc.2026.04.294_bib0142","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.eururo.2023.03.029","article-title":"Epidemiology of bladder cancer in 2023: a systematic review of risk factors","volume":"84","author":"Jubber","year":"2023","journal-title":"Eur Urol"},{"issue":"25","key":"10.1016\/j.urolonc.2026.04.294_bib0143","doi-asserted-by":"crossref","first-page":"17420","DOI":"10.18632\/oncotarget.24724","article-title":"Impact of tobacco smoking on the risk of developing 25 different cancers in the UK: a retrospective study of 422,010 patients followed for up to 30 years","volume":"9","author":"Jacob","year":"2018","journal-title":"Oncotarget"},{"issue":"3","key":"10.1016\/j.urolonc.2026.04.294_bib0144","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1002\/ijc.32420","article-title":"The future burden of kidney and bladder cancers preventable by behavior modification in Australia: a pooled cohort study","volume":"146","author":"Laaksonen","year":"2020","journal-title":"Int J Cancer"},{"issue":"6","key":"10.1016\/j.urolonc.2026.04.294_bib0145","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1007\/s11255-022-03173-w","article-title":"Cigarette smoking and risk of bladder cancer: a dose-response meta-analysis","volume":"54","author":"Zhao","year":"2022","journal-title":"Int Urol Nephrol"},{"issue":"5","key":"10.1016\/j.urolonc.2026.04.294_bib0146","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1158\/1940-6207.CAPR-18-0441","article-title":"Smoking cessation and the risk of bladder cancer among postmenopausal women","volume":"12","author":"Li","year":"2019","journal-title":"Cancer Prev Res (Phila Pa,)"},{"issue":"3","key":"10.1016\/j.urolonc.2026.04.294_bib0147","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1158\/1055-9965.EPI-22-1289","article-title":"Biomarkers of tobacco carcinogenesis in diverse populations: challenges and opportunities","volume":"32","author":"Etemadi","year":"2023","journal-title":"Cancer Epidemiol Biomark Prev : Publ Am Assoc Cancer Res cosponsored Am Soc Prev Oncol"},{"issue":"1","key":"10.1016\/j.urolonc.2026.04.294_bib0148","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.3329\/brc.v11i1.78881","article-title":"Proteomic insights into the health impacts of cigarette smoking: analyzing nicotine, pahs, aromatic amines, and aldehydes","volume":"11","author":"Miah","year":"2025","journal-title":"Bioresearch Commun"},{"key":"10.1016\/j.urolonc.2026.04.294_bib0149","series-title":"Oxidative stress: its mechanisms and impacts on human health and disease onset","author":"Zeliger","year":"2022"},{"key":"10.1016\/j.urolonc.2026.04.294_bib0150","article-title":"Human cancer genomes harbor the mutational signature of tobacco-specific nitrosamines NNN and NNK","author":"Korenjak","year":"2024","journal-title":"bioRxiv"},{"issue":"5","key":"10.1016\/j.urolonc.2026.04.294_bib0151","doi-asserted-by":"crossref","first-page":"355","DOI":"10.2174\/1389200223666220328143828","article-title":"Cytochromes P450: role in carcinogenesis and relevance to cancers","volume":"23","author":"Abu-Bakar","year":"2022","journal-title":"Curr Drug Metab"},{"issue":"3","key":"10.1016\/j.urolonc.2026.04.294_bib0152","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1002\/(SICI)1097-0215(19960126)65:3<314::AID-IJC6>3.0.CO;2-2","article-title":"DNA adducts in urothelial cells: relationship with biomarkers of exposure to arylamines and polycyclic aromatic hydrocarbons from tobacco smoke","volume":"65","author":"Vineis","year":"1996","journal-title":"Int J Cancer"},{"key":"10.1016\/j.urolonc.2026.04.294_bib0153","article-title":"Molecular mechanism in urothelial carcinoma with FGFR3 mutation","volume":"40","author":"Liu","year":"2022","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.urolonc.2026.04.294_bib0154","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3233\/TUB-220032","article-title":"Patterns of mutations in nine cancer-related genes and PAF development among smoking male patients diagnosed with bladder cancer","volume":"45","author":"Alshehri","year":"2023","journal-title":"Tumour Biol : J Int Soc Oncodevelopmental Biol Med"},{"issue":"7","key":"10.1016\/j.urolonc.2026.04.294_bib0155","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1021\/acs.chemrestox.0c00098","article-title":"Novel o-toluidine metabolite in rat urine associated with urinary bladder carcinogenesis","volume":"33","author":"Tajima","year":"2020","journal-title":"Chem Res Toxicol"},{"key":"10.1016\/j.urolonc.2026.04.294_bib0156","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1196\/annals.1371.031","article-title":"Carcinogen exposure and epigenetic silencing in bladder cancer","volume":"1076","author":"Marsit","year":"2006","journal-title":"Ann N Y Acad Sci"},{"issue":"3","key":"10.1016\/j.urolonc.2026.04.294_bib0157","doi-asserted-by":"crossref","first-page":"322","DOI":"10.29235\/1561-8323-2018-62-3-322-328","article-title":"Influence of p16 gene methylation on the risk of progression of non-muscle invasive bladder cancer","volume":"62","author":"Smal","year":"2018","journal-title":"Dokl Natl Acad Sci Belarus"},{"issue":"1","key":"10.1016\/j.urolonc.2026.04.294_bib0158","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1093\/carcin\/bgi172","article-title":"Carcinogen exposure and gene promoter hypermethylation in bladder cancer","volume":"27","author":"Marsit","year":"2006","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.urolonc.2026.04.294_bib0159","doi-asserted-by":"crossref","first-page":"110703","DOI":"10.1016\/j.biopha.2020.110703","article-title":"Expression profile of microRNAs in bladder cancer and their application as biomarkers","volume":"131","author":"Taheri","year":"2020","journal-title":"Biomed Pharmacother"},{"issue":"Suppl 3","key":"10.1016\/j.urolonc.2026.04.294_bib0160","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1186\/s12864-021-08052-9","article-title":"Epigenetic interplay between methylation and miRNA in bladder cancer: focus on isoform expression","volume":"22","author":"Shivakumar","year":"2021","journal-title":"BMC Genom"},{"key":"10.1016\/j.urolonc.2026.04.294_bib0161","series-title":"Cancer","first-page":"67","article-title":"Oxidative stress, epigenetics, and bladder cancer","author":"Boonla","year":"2021"},{"issue":"7794","key":"10.1016\/j.urolonc.2026.04.294_bib0162","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1038\/s41586-020-1961-1","article-title":"Tobacco smoking and somatic mutations in human bronchial epithelium","volume":"578","author":"Yoshida","year":"2020","journal-title":"Nature"},{"issue":"12","key":"10.1016\/j.urolonc.2026.04.294_bib0163","doi-asserted-by":"crossref","first-page":"5076","DOI":"10.1158\/0008-5472.CAN-05-0551","article-title":"TP53 and KRAS mutation load and types in lung cancers in relation to tobacco smoke: distinct patterns in never, former, and current smokers","volume":"65","author":"Le Calvez","year":"2005","journal-title":"Cancer Res"},{"issue":"4 Pt 1","key":"10.1016\/j.urolonc.2026.04.294_bib0164","first-page":"297","article-title":"Comparison of mutations in the p53 and K-ras genes in lung carcinomas from smoking and nonsmoking women","volume":"8","author":"Gealy","year":"1999","journal-title":"Cancer Epidemiol Biomark Prev : Publ Am Assoc Cancer Res cosponsored Am Soc Prev Oncol"},{"issue":"44","key":"10.1016\/j.urolonc.2026.04.294_bib0165","doi-asserted-by":"crossref","first-page":"9694","DOI":"10.3748\/wjg.v22.i44.9694","article-title":"Epidemiology of pancreatic cancer","volume":"22","author":"Ilic","year":"2016","journal-title":"World j Gastroenterol"},{"issue":"2","key":"10.1016\/j.urolonc.2026.04.294_bib0167","first-page":"71","article-title":"Etiology and carcinogenesis of pancreatic ductal adenocarcinoma","volume":"51","author":"Song","year":"2008","journal-title":"Korean J Gastroenterol [Taehan Sohwagi Hakhoe chi]"},{"issue":"5","key":"10.1016\/j.urolonc.2026.04.294_bib0168","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.bpg.2017.09.001","article-title":"Tobacco and alcohol as risk factors for pancreatic cancer","volume":"31","author":"Korc","year":"2017","journal-title":"Best Pract Res, Clin Gastroenterol"},{"issue":"8","key":"10.1016\/j.urolonc.2026.04.294_bib0169","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1038\/s41416-018-0029-6","article-title":"The fraction of cancer attributable to modifiable risk factors in England, Wales, Scotland, Northern Ireland, and the United Kingdom in 2015","volume":"118","author":"Brown","year":"2018","journal-title":"Br J Cancer"},{"issue":"1","key":"10.1016\/j.urolonc.2026.04.294_bib0170","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1080\/0284186X.2018.1518591","article-title":"Occupational variation in bladder cancer in Nordic males adjusted with approximated smoking prevalence","volume":"58","author":"Hadkhale","year":"2019","journal-title":"Acta Oncol (Stockh Swed)"},{"issue":"6","key":"10.1016\/j.urolonc.2026.04.294_bib0171","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1007\/s00345-003-0377-5","article-title":"Occupational exposure and urological cancer","volume":"21","author":"Golka","year":"2004","journal-title":"World J Urol"},{"issue":"10","key":"10.1016\/j.urolonc.2026.04.294_bib0172","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1158\/1055-9965.EPI-07-0184","article-title":"Bulky DNA adduct formation and risk of bladder cancer","volume":"16","author":"Casta\u00f1o-Vinyals","year":"2007","journal-title":"Cancer Epidemiol Biomark Prev : Publ Am Assoc Cancer Res cosponsored Am Soc Prev Oncol"},{"issue":"8","key":"10.1016\/j.urolonc.2026.04.294_bib0173","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1002\/ijc.30593","article-title":"Occupational exposure to solvents and bladder cancer: a population-based case control study in Nordic countries","volume":"140","author":"Hadkhale","year":"2017","journal-title":"Int J Cancer"},{"issue":"3","key":"10.1016\/j.urolonc.2026.04.294_bib0174","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1038\/s41370-024-00651-4","article-title":"Occupational exposure to organic solvents and risk of bladder cancer","volume":"34","author":"Xie","year":"2024","journal-title":"J Expo Sci Environ Epidemiol"},{"issue":"2","key":"10.1016\/j.urolonc.2026.04.294_bib0175","first-page":"176","article-title":"The biochemical carcinogenesis of selected heavy metals in bladder cancer","volume":"61","author":"Rorbach-Dolata","year":"2015","journal-title":"Postepy Biochem"},{"key":"10.1016\/j.urolonc.2026.04.294_bib0176","first-page":"241","article-title":"Epigenetic and epitranscriptomic mechanisms of chromium carcinogenesis","volume":"96","author":"Wang","year":"2023"},{"key":"10.1016\/j.urolonc.2026.04.294_bib0177","article-title":"The dynamic face of cadmium-induced carcinogenesis: mechanisms, emerging trends, and future directions","volume":"6","author":"Ali Hussein","year":"2024","journal-title":"Curr Res Toxicol"},{"issue":"3","key":"10.1016\/j.urolonc.2026.04.294_bib0178","first-page":"222","article-title":"Epigenetics in metal carcinogenesis: nickel, arsenic, chromium and cadmium","volume":"1","author":"Arita","year":"2009","journal-title":"Met : Integr Biometal Sci"},{"issue":"3","key":"10.1016\/j.urolonc.2026.04.294_bib0179","first-page":"223","article-title":"A current global view of environmental and occupational cancers","volume":"29","author":"Yang","year":"2011","journal-title":"J Environ Sci Health, C Environ Carcinog Ecotoxicol Rev"},{"issue":"12","key":"10.1016\/j.urolonc.2026.04.294_bib0180","doi-asserted-by":"crossref","first-page":"875","DOI":"10.3390\/toxics12120875","article-title":"The mechanisms of cadmium toxicity in living organisms","volume":"12","author":"Davidova","year":"2024","journal-title":"Toxics"},{"issue":"12","key":"10.1016\/j.urolonc.2026.04.294_bib0181","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1017\/S0031182009990552","article-title":"A wake up call for urinary schistosomiasis: reconciling research effort with public health importance","volume":"136","author":"Rollinson","year":"2009","journal-title":"Parasitology"},{"issue":"2","key":"10.1016\/j.urolonc.2026.04.294_bib0182","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1111\/j.1464-410X.2010.09622.x","article-title":"Successful control of schistosomiasis and the changing epidemiology of bladder cancer in Egypt","volume":"107","author":"Salem","year":"2011","journal-title":"BJU Int"},{"issue":"6","key":"10.1016\/j.urolonc.2026.04.294_bib0183","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1016\/j.urolonc.2009.09.017","article-title":"Urothelial dysplasia and inflammation induced by Schistosoma haematobium total antigen instillation in mice normal urothelium","volume":"29","author":"Botelho","year":"2011","journal-title":"Urol Oncol"},{"issue":"6","key":"10.1016\/j.urolonc.2026.04.294_bib0184","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1016\/S0022-5347(17)49366-9","article-title":"Incidence of squamous cell carcinoma in patients with long-term catheter drainage","volume":"133","author":"Locke","year":"1985","journal-title":"J Urol"},{"issue":"2","key":"10.1016\/j.urolonc.2026.04.294_bib0185","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/S0090-4295(01)01495-9","article-title":"Transitional cell carcinoma in patients with spinal cord injury: a high risk malignancy?","volume":"59","author":"Pannek","year":"2002","journal-title":"Urology"},{"issue":"8","key":"10.1016\/j.urolonc.2026.04.294_bib0186","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1038\/nrc2886","article-title":"Human papillomavirus oncoproteins: pathways to transformation","volume":"10","author":"Moody","year":"2010","journal-title":"Nat Rev, Cancer"},{"issue":"2","key":"10.1016\/j.urolonc.2026.04.294_bib0187","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1093\/infdis\/jir248","article-title":"Human papillomavirus infection and bladder cancer risk: a meta-analysis","volume":"204","author":"Li","year":"2011","journal-title":"J Infect Dis"},{"issue":"6 Pt 1","key":"10.1016\/j.urolonc.2026.04.294_bib0188","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1016\/j.juro.2006.07.157","article-title":"Meta-analysis of studies analyzing the relationship between bladder cancer and infection by human papillomavirus","volume":"176","author":"Guti\u00e9rrez","year":"2006","journal-title":"J Urol"},{"issue":"4","key":"10.1016\/j.urolonc.2026.04.294_bib0189","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/S0090-4295(97)00305-1","article-title":"Bladder cancer in renal transplant recipients","volume":"50","author":"Buzzeo","year":"1997","journal-title":"Urology"},{"issue":"23","key":"10.1016\/j.urolonc.2026.04.294_bib0190","doi-asserted-by":"crossref","first-page":"2823","DOI":"10.1001\/jama.296.23.2823","article-title":"Cancer incidence before and after kidney transplantation","volume":"296","author":"Vajdic","year":"2006","journal-title":"JAMA"},{"issue":"8","key":"10.1016\/j.urolonc.2026.04.294_bib0191","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1038\/sj.bjc.6605314","article-title":"Glucocorticoid therapy and risk of bladder cancer","volume":"101","author":"Dietrich","year":"2009","journal-title":"Br J Cancer"},{"key":"10.1016\/j.urolonc.2026.04.294_bib0192","first-page":"1","article-title":"Some drinking-water disinfectants and contaminants, including arsenic","volume":"84","author":"Working Group on the Evaluation of Carcinogenic Risks to Humans","year":"2004","journal-title":"IARC Monogr Eval Carcinog Risks Hum"},{"issue":"3","key":"10.1016\/j.urolonc.2026.04.294_bib0193","doi-asserted-by":"crossref","DOI":"10.1177\/1559325819863634","article-title":"Low-level exposure to arsenic in drinking water and risk of lung and bladder cancer: a systematic review and dose-response meta-analysis","volume":"17","author":"Boffetta","year":"2019","journal-title":"Dose-Response : Publ Int Hormesis Soc"},{"key":"10.1016\/j.urolonc.2026.04.294_bib0194","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.puhe.2021.11.019","article-title":"Chronic exposure to nitrate in drinking water and the risk of bladder cancer: a meta-analysis of epidemiological evidence","volume":"203","author":"Arafa","year":"2022","journal-title":"Public Health"},{"key":"10.1016\/j.urolonc.2026.04.294_bib0195","doi-asserted-by":"crossref","DOI":"10.1016\/j.watres.2022.118202","article-title":"Chlorination by-products in drinking water and risk of bladder cancer - A population-based cohort study","volume":"214","author":"Helte","year":"2022","journal-title":"Water Res"},{"key":"10.1016\/j.urolonc.2026.04.294_bib0196","doi-asserted-by":"crossref","DOI":"10.1016\/j.gene.2020.144924","article-title":"N-acetyltransferase 2 polymorphism is associated with bladder cancer risk: an updated meta-analysis based on 54 case-control studies","volume":"757","author":"Song","year":"2020","journal-title":"Gene"},{"issue":"11","key":"10.1016\/j.urolonc.2026.04.294_bib0197","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1038\/s41591-022-02014-8","article-title":"Influence of the microbiome, diet and genetics on inter-individual variation in the human plasma metabolome","volume":"28","author":"Chen","year":"2022","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.urolonc.2026.04.294_bib0198","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1186\/s12885-018-5014-1","article-title":"Association of Glutathione S-transferase gene polymorphism with bladder cancer susceptibility","volume":"18","author":"Zhou","year":"2018","journal-title":"BMC Cancer"},{"key":"10.1016\/j.urolonc.2026.04.294_bib0199","doi-asserted-by":"crossref","DOI":"10.1016\/j.gene.2019.144077","article-title":"Glutathione S-transferase pi 1 (GSTP1) gene 313 A\/G (rs1695) polymorphism is associated with the risk of urinary bladder cancer: evidence from a systematic review and meta-analysis based on 34 case-control studies","volume":"719","author":"Song","year":"2019","journal-title":"Gene"},{"issue":"1","key":"10.1016\/j.urolonc.2026.04.294_bib0200","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1093\/toxsci\/kfaa087","article-title":"Effects of arsenic (+3 Oxidation State) methyltransferase gene polymorphisms and expression on bladder cancer: evidence from a systematic review, meta-analysis and TCGA dataset","volume":"177","author":"Song","year":"2020","journal-title":"Toxicol Sci : Off J Soc Toxicol"},{"key":"10.1016\/j.urolonc.2026.04.294_bib0201","doi-asserted-by":"crossref","first-page":"587","DOI":"10.2147\/CMAR.S185867","article-title":"High prevalence of secondary bladder cancer in men on radiotherapy for prostate cancer: evidence from a meta-analysis","volume":"11","author":"Zhao","year":"2019","journal-title":"Cancer Manag Res"},{"issue":"6","key":"10.1016\/j.urolonc.2026.04.294_bib0202","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1111\/bju.14841","article-title":"Long-term incidence of secondary bladder and rectal cancer in patients treated with brachytherapy for localized prostate cancer: a large-scale population-based analysis","volume":"124","author":"Mazzone","year":"2019","journal-title":"BJU Int"},{"issue":"11","key":"10.1016\/j.urolonc.2026.04.294_bib0203","doi-asserted-by":"crossref","first-page":"2393","DOI":"10.1007\/s00345-019-02690-1","article-title":"Association of body mass index with bladder cancer risk in men depends on abdominal obesity","volume":"37","author":"Choi","year":"2019","journal-title":"World J Urol"},{"issue":"12","key":"10.1016\/j.urolonc.2026.04.294_bib0204","doi-asserted-by":"crossref","first-page":"3071","DOI":"10.1002\/ijc.31597","article-title":"Risk of bladder cancer by disease severity in relation to metabolic factors and smoking: a prospective pooled cohort study of 800,000 men and women","volume":"143","author":"Teleka","year":"2018","journal-title":"Int J Cancer"},{"key":"10.1016\/j.urolonc.2026.04.294_bib0205","doi-asserted-by":"crossref","DOI":"10.4178\/epih.e2022050","article-title":"The relationship between metabolic syndrome and its components with bladder cancer: a systematic review and meta-analysis of cohort studies","volume":"44","author":"Ahmadinezhad","year":"2022","journal-title":"Epidemiol Health"},{"issue":"9","key":"10.1016\/j.urolonc.2026.04.294_bib0206","first-page":"441","article-title":"Incidence of bladder cancer in type 2 diabetes mellitus patients: a population-based cohort study","volume":"56","author":"Pan","year":"2020","journal-title":"Med (Kaunas Lith)"},{"issue":"3","key":"10.1016\/j.urolonc.2026.04.294_bib0207","doi-asserted-by":"crossref","first-page":"641","DOI":"10.3904\/kjim.2017.402","article-title":"Site-specific cancer risk in patients with type 2 diabetes: a nationwide population-based cohort study in Korea","volume":"35","author":"Kim","year":"2020","journal-title":"Korean J Intern Med"},{"key":"10.1016\/j.urolonc.2026.04.294_bib0208","doi-asserted-by":"crossref","DOI":"10.1177\/20587392211016117","article-title":"Atopy, asthma, and risk of bladder cancer: systematic review and meta-analysis of cohort studies","volume":"19","author":"Feng","year":"2021","journal-title":"Eur J Inflamm"},{"issue":"2","key":"10.1016\/j.urolonc.2026.04.294_bib0209","doi-asserted-by":"crossref","first-page":"460","DOI":"10.3904\/kjim.2020.259","article-title":"Cancer risk in Korean patients with gout","volume":"37","author":"Oh","year":"2022","journal-title":"Korean J Intern Med"},{"key":"10.1016\/j.urolonc.2026.04.294_bib0210","series-title":"Seminars in arthritis and rheumatism","first-page":"692","article-title":"The cancer risk according to three subtypes of ANCA-associated vasculitis: a propensity score-matched analysis of a nationwide study","volume":"51","author":"Choi","year":"2021"},{"issue":"9","key":"10.1016\/j.urolonc.2026.04.294_bib0211","doi-asserted-by":"crossref","first-page":"614","DOI":"10.34172\/aim.2020.72","article-title":"An updated meta-analysis on the risk of urologic cancer in patients with systemic Lupus erythematosus","volume":"23","author":"Yeo","year":"2020","journal-title":"Arch Iran Med"},{"issue":"6","key":"10.1016\/j.urolonc.2026.04.294_bib0212","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1016\/j.transproceed.2018.02.146","article-title":"Solid organ cancer and melanoma in kidney transplant recipients: tumorTx base preliminary results","volume":"50","author":"Lizakowski","year":"2018","journal-title":"Transplant Proc"},{"issue":"4","key":"10.1016\/j.urolonc.2026.04.294_bib0213","doi-asserted-by":"crossref","DOI":"10.1016\/j.clinre.2020.07.019","article-title":"Risk factors of de novo malignancies after liver transplantation: a French national study on 11004 adult patients","volume":"45","author":"Altieri","year":"2021","journal-title":"Clin Res Hepatol Gastroenterol"},{"issue":"3","key":"10.1016\/j.urolonc.2026.04.294_bib0214","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1007\/s11255-020-02659-9","article-title":"Urological second malignant neoplasms in testicular nonseminoma survivors: a population-based analysis","volume":"53","author":"Li","year":"2021","journal-title":"Int Urol Nephrol"},{"issue":"19","key":"10.1016\/j.urolonc.2026.04.294_bib0215","doi-asserted-by":"crossref","first-page":"3075","DOI":"10.1002\/cncr.30164","article-title":"Risk of second primary malignancies among cancer survivors in the United States, 1992 through 2008","volume":"122","author":"Donin","year":"2016","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.urolonc.2026.04.294_bib0216","doi-asserted-by":"crossref","first-page":"znad377","DOI":"10.1093\/bjs\/znad377","article-title":"Correlation between second and first primary cancer: systematic review and meta-analysis of 9 million cancer patients","volume":"111","author":"Wang","year":"2024","journal-title":"Br J Surg"},{"issue":"1","key":"10.1016\/j.urolonc.2026.04.294_bib0217","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1186\/s12885-018-4530-3","article-title":"Risk of second primary cancer among bladder cancer patients: a population-based cohort study in Korea","volume":"18","author":"Kwon","year":"2018","journal-title":"BMC Cancer"},{"issue":"1","key":"10.1016\/j.urolonc.2026.04.294_bib0218","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S0022-5347(01)65281-9","article-title":"Coincidence of bladder and prostate cancer","volume":"157","author":"Chun","year":"1997","journal-title":"J Urol"},{"issue":"1","key":"10.1016\/j.urolonc.2026.04.294_bib0219","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/S0022-5347(05)64056-6","article-title":"Transitional cell carcinoma involving the prostate: a clinicopathological retrospective study of 76 cases","volume":"169","author":"Njinou Ngninkeu","year":"2003","journal-title":"J Urol"},{"issue":"1","key":"10.1016\/j.urolonc.2026.04.294_bib0220","first-page":"47","article-title":"Relationship between tP53 AND fgfr3 mutations in superficial bladder cancer","volume":"8","author":"Paul\u00b9","year":"2012","journal-title":"Med Connect| Conex Med"},{"issue":"12","key":"10.1016\/j.urolonc.2026.04.294_bib0221","doi-asserted-by":"crossref","DOI":"10.18632\/oncotarget.7343","article-title":"Retrospective study testing next generation sequencing of selected cancer-associated genes in resected prostate cancer","volume":"7","author":"Iacono","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.urolonc.2026.04.294_bib0222","series-title":"Estudi dels gens FGFR3, EGFR, PTEN, CXCR4 i del gen de fusi\u00f3 TMPRSS2-ERG en c\u00e0ncer de pr\u00f2stata","author":"de Muga Salleras","year":"2012"},{"issue":"20","key":"10.1016\/j.urolonc.2026.04.294_bib0223","doi-asserted-by":"crossref","DOI":"10.3390\/ijms222011088","article-title":"Role of PI3K-AKT-mTOR pathway as a pro-survival signaling and resistance-mediating mechanism to therapy of prostate cancer","volume":"22","author":"Pungsrinont","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"9","key":"10.1016\/j.urolonc.2026.04.294_bib0224","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1158\/1940-6207.CAPR-10-0039","article-title":"Global reactivation of epigenetically silenced genes in prostate cancer","volume":"3","author":"Ibragimova","year":"2010","journal-title":"Cancer Prev Res (Phila Pa,)"},{"key":"10.1016\/j.urolonc.2026.04.294_bib0225","first-page":"35","article-title":"Epigenetic markers for bladder cancer in urine","volume":"2","author":"Kim","year":"2007","journal-title":"Transl Oncogenomics"},{"key":"10.1016\/j.urolonc.2026.04.294_bib0226","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2024.1437951","article-title":"MicroRNA-21 in urologic cancers: from molecular mechanisms to clinical implications","volume":"12","author":"Gan","year":"2024","journal-title":"Front Cell Dev Biol"},{"issue":"7","key":"10.1016\/j.urolonc.2026.04.294_bib0227","doi-asserted-by":"crossref","first-page":"933","DOI":"10.2174\/1381612822666151209153729","article-title":"MicroRNA-34a and its target genes: key factors in cancer multidrug resistance","volume":"22","author":"Ghandadi","year":"2016","journal-title":"Curr Pharm Des"},{"issue":"3","key":"10.1016\/j.urolonc.2026.04.294_bib0228","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.urolonc.2006.10.002","article-title":"Chronic inflammation and bladder cancer","volume":"25","author":"Michaud","year":"2007","journal-title":"Urol Oncol"},{"issue":"7","key":"10.1016\/j.urolonc.2026.04.294_bib0229","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.21037\/tau-23-667","article-title":"Risk factors for secondary bladder cancer following prostate cancer radiotherapy","volume":"13","author":"Jahrei\u00df","year":"2024","journal-title":"Transl Androl Urol"},{"issue":"6 Suppl 4","key":"10.1016\/j.urolonc.2026.04.294_bib0230","first-page":"S220","article-title":"Is sparing the prostate still considered radical cystectomy? The case against prostate-sparing cystectomy for bladder cancer","volume":"3","author":"Kotb","year":"2009","journal-title":"Can Urol Assoc J = J Assoc urol du Can"},{"key":"10.1016\/j.urolonc.2026.04.294_bib0232","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2023.41.16_suppl.e16581","article-title":"Prediction of 6-year risk of bladder cancer using the HUNT lung cancer risk model in ever-smokers: a HUNT study","volume":"41","author":"R\u00f8e","year":"2023","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.urolonc.2026.04.294_bib0233","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1097\/EDE.0b013e31829e3e03","article-title":"Arsenic, tobacco smoke, and occupation: associations of multiple agents with lung and bladder cancer","volume":"24","author":"Ferreccio","year":"2013","journal-title":"Epidemiology"},{"issue":"Suppl 3","key":"10.1016\/j.urolonc.2026.04.294_bib0234","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1289\/ehp.96104s3553","article-title":"Cigarette smoking and p53 mutations in lung cancer and bladder cancer","volume":"104","author":"Husgafvel-Pursiainen","year":"1996","journal-title":"Environ Health Perspect"},{"issue":"1_Supplement","key":"10.1016\/j.urolonc.2026.04.294_bib0235","doi-asserted-by":"crossref","first-page":"P012","DOI":"10.1158\/1940-6215.PrecPrev22-P012","article-title":"Abstract P012: mutation hotspots in skin, bladder, and lung cancer as targets of carcinogenic risk assessment in clinically normal-appearing tissue","volume":"16","author":"Grant","year":"2023","journal-title":"Cancer Prev Res"},{"issue":"7471","key":"10.1016\/j.urolonc.2026.04.294_bib0236","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1038\/nature12634","article-title":"Mutational landscape and significance across 12 major cancer types","volume":"502","author":"Kandoth","year":"2013","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.urolonc.2026.04.294_bib0237","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.3390\/cells10051154","article-title":"Targeting the fibroblast growth factor receptor (FGFR) family in lung cancer","volume":"10","author":"Pacini","year":"2021","journal-title":"Cells"},{"issue":"18","key":"10.1016\/j.urolonc.2026.04.294_bib0238","doi-asserted-by":"crossref","DOI":"10.3390\/ijms231810506","article-title":"FGFR1\u20134 RNA-based gene alteration and expression analysis in squamous non-small cell lung cancer","volume":"23","author":"Moes-Sosnowska","year":"2022","journal-title":"Int J Mol Sci"},{"issue":"2","key":"10.1016\/j.urolonc.2026.04.294_bib0239","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/s00428-014-1596-4","article-title":"FGFR3 mutations, but not FGFR3 expression and FGFR3 copy-number variations, are associated with favourable non-muscle invasive bladder cancer","volume":"465","author":"Neuzillet","year":"2014","journal-title":"Virchows Arch : Int J Pathol"},{"issue":"8","key":"10.1016\/j.urolonc.2026.04.294_bib0240","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1158\/1078-0432.CCR-17-2655","article-title":"Small-cell carcinomas of the bladder and lung are characterized by a convergent but distinct pathogenesis","volume":"24","author":"Chang","year":"2018","journal-title":"Clin Cancer Res : Off J Am Assoc Cancer Res"},{"key":"10.1016\/j.urolonc.2026.04.294_bib0241","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.fct.2019.05.016","article-title":"Paederia foetida induces anticancer activity by modulating chromatin modification enzymes and altering pro-inflammatory cytokine gene expression in human prostate cancer cells","volume":"130","author":"Pradhan","year":"2019","journal-title":"Food Chem Toxicol : Int J Publ Br Ind Biol Res Assoc"},{"issue":"1","key":"10.1016\/j.urolonc.2026.04.294_bib0242","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.gene.2016.01.029","article-title":"Epigenetic drift towards histone modifications regulates CAV1 gene expression in colon cancer","volume":"581","author":"Deb","year":"2016","journal-title":"Gene"},{"issue":"8","key":"10.1016\/j.urolonc.2026.04.294_bib0243","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1016\/j.bbadis.2015.04.021","article-title":"Clusterin gene is predominantly regulated by histone modifications in human colon cancer and ectopic expression of the nuclear isoform induces cell death","volume":"1852","author":"Deb","year":"2015","journal-title":"Biochim biophys acta"},{"key":"10.1016\/j.urolonc.2026.04.294_bib0244","article-title":"Modulation of H3K4 trimethylation by KDM5A and MLLs impacts metabolic adaptability in prostate and cervical cancer cells","author":"Kirtana","year":"2024","journal-title":"bioRxiv"},{"issue":"4","key":"10.1016\/j.urolonc.2026.04.294_bib0245","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbagrm.2023.194986","article-title":"KDM5A noncanonically binds antagonists MLL1\/2 to mediate gene regulation and promotes epithelial to mesenchymal transition","volume":"1866","author":"Kirtana","year":"2023","journal-title":"Biochim Biophys Acta Gene Regul Mech"},{"issue":"2","key":"10.1016\/j.urolonc.2026.04.294_bib0246","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.yexcr.2016.07.023","article-title":"DNA methylation and not H3K4 trimethylation dictates the expression status of miR-152 gene which inhibits migration of breast cancer cells via DNMT1\/CDH1 loop","volume":"346","author":"Sengupta","year":"2016","journal-title":"Exp Cell Res"},{"issue":"6","key":"10.1016\/j.urolonc.2026.04.294_bib0247","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1016\/j.bbadis.2019.04.002","article-title":"Epigenetic silencing of genes enhanced by collective role of reactive oxygen species and MAPK signaling downstream ERK\/snail axis: ectopic application of hydrogen peroxide repress CDH1 gene by enhanced DNA methyltransferase activity in human breast cancer","volume":"1865","author":"Pradhan","year":"2019","journal-title":"Biochim biophys acta, Mol Basis Dis"},{"issue":"1","key":"10.1016\/j.urolonc.2026.04.294_bib0248","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1039\/C5MB00412H","article-title":"Insights into the molecular interactions of thymoquinone with histone deacetylase: evaluation of the therapeutic intervention potential against breast cancer","volume":"12","author":"Parbin","year":"2016","journal-title":"Mol bioSyst"},{"issue":"3","key":"10.1016\/j.urolonc.2026.04.294_bib0249","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/S0094-0143(21)00413-4","article-title":"Diagnosis and staging of bladder cancer","volume":"19","author":"Cummings","year":"1992","journal-title":"Urol Clin N Am"},{"issue":"4","key":"10.1016\/j.urolonc.2026.04.294_bib0250","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1016\/j.euf.2021.09.025","article-title":"Underutilization of blue light cystoscopy for bladder cancer in the United States","volume":"8","author":"Lewicki","year":"2022","journal-title":"Eur Urol Focus"},{"issue":"8","key":"10.1016\/j.urolonc.2026.04.294_bib0251","first-page":"749","article-title":"Bladder cancer: current challenges and future directions","volume":"57","author":"Dobruch","year":"2021","journal-title":"Med (Kaunas Lith)"},{"issue":"10364","key":"10.1016\/j.urolonc.2026.04.294_bib0252","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1016\/S0140-6736(22)01188-6","article-title":"Current best practice for bladder cancer: a narrative review of diagnostics and treatments","author":"Comp\u00e9rat","year":"2022","journal-title":"Lancet (Lond Engl) 400"},{"key":"10.1016\/j.urolonc.2026.04.294_bib0253","article-title":"Mechanisms of BCG in the treatment of bladder cancer-current understanding and the prospect","volume":"129","author":"Han","year":"2020","journal-title":"Biomed Pharmacother = Biomed Pharmacother"},{"issue":"6","key":"10.1016\/j.urolonc.2026.04.294_bib0254","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/j.acuro.2013.03.001","article-title":"The study of DNA methylation in urological cancer: present and future","volume":"37","author":"Andr\u00e9s","year":"2013","journal-title":"Actas Urol Esp"},{"issue":"3","key":"10.1016\/j.urolonc.2026.04.294_bib0255","doi-asserted-by":"crossref","first-page":"615","DOI":"10.3390\/cancers15030615","article-title":"A novel methylation marker NRN1 plus TERT and FGFR3 mutation using urine sediment enables the detection of urothelial bladder carcinoma","volume":"15","author":"Zhang","year":"2023","journal-title":"Cancers"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143926004989?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143926004989?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T14:27:11Z","timestamp":1793802431000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143926004989"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":254,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S1078143926004989"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2026.04.294","relation":{},"ISSN":["1078-1439"],"issn-type":[{"value":"1078-1439","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Epigenetic signatures and risk determinants in bladder cancer: Implications for diagnostic and therapeutic interventions","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2026.04.294","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}